SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (11766)11/26/1997 3:02:00 PM
From: Henry Niman  Read Replies (1) | Respond to of 32384
 
Andy, I think that the new drug to be licensed from LLY includes milestone payments of $20 million, and since it will be already approved when LGND takes out the license, I suspect that the $20 million will be tied to sales.
As far as the fusion toxin for the brain cancer is concerned, it sounded like SRGN technology, but I haven't seen the article yet. SRGN takes a ligand such as IL-2, EGF, (or transferin?) and fuses it to a diptheria toxin which then kills the cells with appropriate receptors on their surface (after they take up the ligand and toxin).



To: Andrew H who wrote (11766)11/26/1997 5:29:00 PM
From: Harrison Hickman  Read Replies (1) | Respond to of 32384
 
Andrew H.

I guess I become easily confused with age. Prior to and in the immediate aftermath of "the deal," I thought we were instructed not to be concerned about the dilution. Waiting for the rest of the market to become as smart as we are is beginning to tax my patience. I'd rather them tax my capital gains. #:>)

Harrison Hickman


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News